答:公司血透产品已布局海外市场，但整体规模仍较小，处于拓展阶段，如公司血液透析设备、透析 器、透析液过滤器等产品已在海外销售。2025年上半年公司海外血透收入增长121.29%，业务向好发展 效果初现。未来，公司将持续关注并积极把握拓展海外血透市场的机会。 格隆汇12月15日丨宝莱特(300246.SZ)在投资者关系中表示，有被问到:请问公司血透产品出海情况？后 续会提高对海外市场的重视吗？ ...

证券代码：300246 证券简称：宝莱特 1、公司近年来加强研发创新，推出了哪些新产品？ 答：近年公司推出了 D800 系列血液透析设备、P 系列插件式监护仪、 家用腹膜透析机、S 系列输注液泵、电子尿量计量仪、遥测监护仪、可视喉 镜、肠内营养泵等有源产品。其中不乏拥有行业领先技术及行业首创功能的 亮点产品，如 P 系列插件式监护仪，曾荣获"红点奖"，拥有行业领先的抗电 刀干扰技术，以及智能化预警、高端参数集成分析、智能语音助手和 BOA 麻醉平衡界面等功能；D800Plus 血液透析滤过设备，为国内首创三泵机型， 拥有混合稀释置换模式，能更好地维持透析膜对水及溶质的转运，有效改善 透析治疗效果；PD600 腹膜透析设备，轻量化设计，可远程监控，并拥有智 能语音、视频操作引导、多设备数据收集及蓝牙传送等实用功能。 2、医疗设备"以旧换新"政策，对公司的两大业务板块具体有哪些积极影 响？ 答：上述政策的施行，对公司监护仪业务的影响是积极的，监护设备更 新需求增加，政策推动公立医院、基层医疗机构淘汰老旧设备，公司的中高 端监护仪有望受益于采购增量；基层医疗扩容（县域医共体、社区医院）带 来监护仪的替代需求，其对公 ...

Core Viewpoint - The article discusses the blood purification device industry, highlighting the increasing prevalence of End-Stage Renal Disease (ESRD) and the growth potential of blood purification technologies in response to this global health challenge [18][21]. Market Overview - The global ESRD patient population is projected to grow from 91.33 million in 2019 to 148.51 million by 2030, with a CAGR of 4.2% [18][19]. - In China, the ESRD patient population is expected to increase from 3.025 million in 2019 to 6.132 million by 2030, with a CAGR of 5.8% [20][18]. Treatment Methods - Blood purification is the most widely used treatment for ESRD, offering higher survival rates compared to kidney transplantation and conservative treatment [21]. - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.069 million in 2023, with a CAGR of 9.8%, and is expected to reach 3.791 million by 2030, with a CAGR of 19.8% [21][23]. Blood Purification Technologies - The main blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most mature and widely applied [29]. - Hemodialysis effectively removes harmful substances and excess fluid from the blood, making it suitable for patients at various disease stages [29]. Market Size and Growth - The Chinese blood dialysis device market is projected to grow from CNY 11.63 billion in 2019 to CNY 51.52 billion by 2030, with a CAGR of 19.9% from 2023 to 2030 [30][28]. - The market share of blood dialysis devices in China is expected to see significant growth, with specific segments like blood dialysis machines and consumables also experiencing robust growth rates [30]. Competitive Landscape - Domestic companies are rapidly catching up with international competitors in the blood purification consumables sector, achieving nearly 50% market share in dialysis filters [31]. - The competitive landscape for blood dialysis machines is evolving, with domestic manufacturers improving their technology and performance to match imported products [37][33]. Policy and Market Dynamics - The article notes that the Chinese government has been implementing centralized procurement policies, leading to significant price reductions and accelerating the domestic replacement process in the blood purification market [36][35].

Investment Rating - The report does not explicitly provide an investment rating for the blood purification device industry Core Insights - The report highlights the increasing prevalence of End-Stage Renal Disease (ESRD) globally and in China, with the number of patients expected to rise significantly by 2030, indicating a growing market for blood purification devices [13][15] - Blood purification is identified as the most widely used treatment method for ESRD, with a higher survival rate compared to other treatments like kidney transplantation and conservative treatment [19] - The Chinese blood purification device market is projected to grow rapidly, driven by an increase in ESRD patients, improved reimbursement policies, and advancements in dialysis infrastructure [26] Market Overview - The global ESRD patient population increased from 9.13 million in 2019 to 11.14 million in 2023, with a CAGR of 5.1%, and is expected to reach 14.85 million by 2030 [13][14] - In China, the ESRD patient population grew from 3.03 million in 2019 to 4.13 million in 2023, with a CAGR of 8.1%, projected to reach 6.13 million by 2030 [15] - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.07 million in 2023, with a CAGR of 9.8%, expected to reach 3.79 million by 2030 [19][18] Treatment Methods - Blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most common and effective method for ESRD patients [23] - Hemodialysis is noted for its effectiveness in removing toxins and excess fluid, while peritoneal dialysis is gaining traction due to its home treatment capabilities [21][23] Market Size and Growth - The Chinese blood purification device market size increased from 116.3 billion yuan in 2019 to 145.0 billion yuan in 2023, with a CAGR of 5.7%, and is expected to reach 515.2 billion yuan by 2030, with a projected CAGR of 19.9% from 2023 to 2030 [26] - The market for blood purification devices is segmented into blood purification machines, blood purification consumables, and other related equipment, with significant growth expected across all segments [26] Competitive Landscape - Domestic companies are rapidly catching up to international competitors in the blood purification consumables market, achieving nearly 50% market share in key areas [27] - The report indicates that the domestic market for blood purification machines still has room for growth, as these products have historically relied on imports due to high technical barriers [27][34] - The report emphasizes that domestic manufacturers are improving their technology and performance, positioning themselves to capture a larger market share [29][34]

证券日报网讯 11月25日晚间，宝莱特发布公告称，根据相关规定，"宝莱转债"将于公司2025年前三季 度权益分派股权登记日后的第一个交易日，即2025年11月26日（除权除息日）起恢复转股。敬请公司可 转换公司债券持有人留意。 （文章来源：证券日报） ...

| 股票简称：宝莱特 | 股票代码：300246 | | --- | --- | | 债券简称：宝莱转债 | 债券代码：123065 | 财通证券股份有限公司 关于广东宝莱特医用科技股份有限公司 向不特定对象发行可转换公司债券 2025 年度第 1 次临时受托管理事务报告 债券受托管理人 二零二五年十一月 （四）债券期限：6 年。 （五）债券利率：第一年为 0.4%、第二年为 0.7%、第三年为 1.0%、第四年 为 1.8%、第五年为 2.5%、第六年为 3.5%。 声 明 本报告依据《公司债券发行与交易管理办法》《公司债券受托管理人执业行 为准则》《广东宝莱特医用科技股份有限公司与财通证券股份有限公司关于广东 宝莱特医用科技股份有限公司 2020 年向不特定对象发行可转换公司债券之受托 管理协议》（以下简称 "《债券受托管理协议》"）《广东宝莱特医用科技股 份有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称 "《募集说明书》"）等公开信息披露文件以及广东宝莱特医用科技股份有限公 司（以下简称"公司"）出具的相关公告、说明文件等，由债券受托管理人财通 证券股份有限公司（以下简称"财通证券" ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-085 债券代码：123065 债券简称：宝莱转债 根据相关规定，"宝莱转债"将于公司2025年前三季度权益分派股权登记日 后的第一个交易日，即2025年11月26日（除权除息日）起恢复转股。敬请公司可 转换公司债券持有人留意。 特此公告。 广东宝莱特医用科技股份有限公司 1、债券代码：123065 2、债券简称：宝莱转债 3、可转换公司债券转股的起止日期：2021 年 3 月 11 日至 2026 年 9 月 3 日 4、暂停转股时间：2025 年 11 月 18 日至 2025 年 11 月 25 日 广东宝莱特医用科技股份有限公司 关于宝莱转债恢复转股的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 5、恢复转股时间：2025 年 11 月 26 日 广东宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"）因实 施2025年前三季度权益分派，根据《广东宝莱特医用科技股份有限公司创业板向 不特定对象发行可转换公司债券募集说明书》及《深圳证券交易所创业板上市公 司自律监管 ...

分组1 - 莱绅通灵 announced a cash dividend of 0.10 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [1] - 卫信康 declared a cash dividend of 0.147 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [1] - 宏辉果蔬 issued a cash dividend of 0.005 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [1] 分组2 - 杭叉集团 reported a cash dividend of 0.2 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [2] - 新坐标 announced a cash dividend of 0.25 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [2] - 厦门象屿 declared a cash dividend of 0.1 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [2] 分组3 - 鼎泰高科 announced a cash dividend of 4.0 yuan for every 10 shares (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [3] - 宝莱特 declared a cash dividend of 0.494386 yuan for every 10 shares (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [3] - 华明装备 issued a cash dividend of 0.1999450 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [3] 分组4 - 金岭矿业 announced a cash dividend of 0.50 yuan for every 10 shares (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [4]

Core Points - The company Baolite announced a cash dividend distribution plan for the first three quarters of 2025, proposing a payment of 0.500000 RMB per 10 shares to all shareholders [2] - The total number of shares used as the basis for the distribution is 261,607,088 shares, excluding 2,970,600 shares that have been repurchased [2] - The record date for the dividend is set for November 25, 2025, and the ex-dividend date is November 26, 2025 [2]

证券代码：300246 证券简称：宝莱特 公告编号：2025-083 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025 年前三季度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，回购专用账户中持有的本公司股份不享 有参与利润分配的权利。因此，公司 2025 年前三季度权益分派以公司实施 2025 年前三季度利润分配方案时股权登记日总股本 264,577,688 股剔除已回购股份 2,970,600 股后的 261,607,088 股为基数。 2．公司本次年度权益分派按照"分配比例不变"（即向全体股东每 10 股 派发现金红利人民币 0.50 元（含税），不送红股，不以公积金转增股本）的原 则执行，合计派发现金红利 13,080,354.40 元人民币（含税）。 3．因回购股份不参与分红，本次权益分派实施后，根据股票市值不变原则， 实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例 ...